# Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

> **NCT03486873** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3500 (estimated)

## Conditions studied

- Solid Tumors
- Hematologic Malignancies

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Standard of Care (SOC)
- **DRUG:** Lenvatinib
- **DRUG:** Olaparib
- **DRUG:** MK-4280
- **BIOLOGICAL:** MK-4280A
- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa

## Key facts

- **NCT ID:** NCT03486873
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-21
- **Primary completion:** 2043-08-04
- **Final completion:** 2043-08-04
- **Target enrollment:** 3500 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486873, "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT03486873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*